Search Results for: mscs

Interview with Bob Lanza on new ACT MSCs for MS paper

I did a brief email Q&A interview with Dr. Bob Lanza of Advanced Cell Technology (ACT) on their new hES MSCs pre-clinical data for Multiple Sclerosis. I discussed the paper itself in a concise review yesterday here. Thanks to Dr. Lanza for doing the interview. 1. Were you surprised at the fact that the therapeutic …

Interview with Bob Lanza on new ACT MSCs for MS paper Read More »

Review of New ACT Paper on hESC-derived MSCs

advanced-cell-technology-150x1501

Advanced Cell Technology (ACT; $ACTC) has a new paper out on using human embryonic stem cells (hESC) to make MSCs with potentially powerful therapeutic potential. The paper, entitled Mesenchymal stem cell population derived from human pluripotent stem cells displays potent immunomodulatory and therapeutic properties, was published in the journal Stem Cells and Development. What’s the scoop on this …

Review of New ACT Paper on hESC-derived MSCs Read More »

ACT patent filing for MSCs: of Dancing Mice & Multiple Sclerosis

dancing-mice

Is Advanced Cell Technology (ACT) on the road to cure Multiple Sclerosis (MS) using stem cells and specifically MSCs? Some folks seem to think it’s quite possible, but I remain skeptical. Still there have been some interesting developments. ACT has a relatively new patent filing for a mesenchymal stromal cell (MSC) product that was just …

ACT patent filing for MSCs: of Dancing Mice & Multiple Sclerosis Read More »

Interview with Arnold Caplan, Part 3: challenges & opportunities for clinical use of MSCs

I recently had a phone interview with Dr. Arnold Caplan, the founder of the MSC field. You can read parts 1 and 2 of the interview here and here. Today’s post, part 3, is focused on clinical use of MSCs. I want to start off today’s post with a wonderful quote from Caplan: “All MSCs …

Interview with Arnold Caplan, Part 3: challenges & opportunities for clinical use of MSCs Read More »

Lessons from 4 stem cell stocks that tanked: Celularity, Athersys, Mesoblast, BrainStorm Cell

Athersys stock, Athersys, stem cell stocks

I’ve been following 24 stem cell stocks for a few years. I haven’t invested in them or any others recently, but rather just find them interesting. How are these doing in 2023? Mostly not great. In some cases, it is downright disastrous. Let’s take a quick look at four stocks very much in the news over …

Lessons from 4 stem cell stocks that tanked: Celularity, Athersys, Mesoblast, BrainStorm Cell Read More »

Burst Biologics unapproved biologic used by Weill Cornell: was there a cover-up?

Burst Biologics, Christopher Jones

The New York Times just broke a story on Burst Biologics and Weill Cornell that fits with long-standing troubling questions about regenerative biologics producers. The story also bears on the doctors and hospitals like Weill Cornell that were or are customers of the suppliers. Further, what is the FDA’s role in all of this? The …

Burst Biologics unapproved biologic used by Weill Cornell: was there a cover-up? Read More »

Weekly reads: stem cell therapy for eyes research, DMD, cheating death, cancer sensors

stem cell therapy

Many avenues are being pursued to get stem cell therapy to the clinic for eye conditions. These different approaches employ a variety of stem cell types. In some cases, such as with iPS cells, the stem cells themselves are not transplanted. Instead, the iPS cells are used to make differentiated eye cells, such as RPE …

Weekly reads: stem cell therapy for eyes research, DMD, cheating death, cancer sensors Read More »

Weekly reads: embryonic stem cells, Parkinson’s, Alzheimer’s

Knoepfler lab stem cells

Early during my postdoc I was primarily interested in the role of Myc genes both in cancer and in stem cells, work that later included embryonic stem cells. These cells are often called ES cells. At first I first started studying N-Myc in neural stem cells using a conditional knockout approach. However, soon after I was …

Weekly reads: embryonic stem cells, Parkinson’s, Alzheimer’s Read More »

Weekly reads: BioCardia, HeLa suit, illegal bio lab in CA

mesenchymal cells

A days ago the news came about Mesoblast not getting FDA approval for its MSC product for GvHD. The MSC area has had a rough few years with various clinical trials including for COVID. The “stem cells for heart disease” arena has also had a tough time. Here’s more news along these lines: BioCardia pauses enrollment in PhIII trial …

Weekly reads: BioCardia, HeLa suit, illegal bio lab in CA Read More »

Update on stem cells & cell therapy for COVID trials

cell therapy for COVID

From the beginning of the pandemic, I have been mostly skeptical about the idea of cell therapy for COVID including stem cell therapies. However, at the same time, I’ve closely followed the data, especially up until 2022. Now having just had a nasty bout with COVID myself for the first time this summer, I recently …

Update on stem cells & cell therapy for COVID trials Read More »